| Ytd | 4.14% | |
| 1y | 62.22% |
| Open | 10.89 | Prev Close | 10.89 | Low | 10.82 | High | 10.89 | Mkt Cap | 966.75M |
| Vol | 21.17K | Avg Vol | 1.73M | EPS | -3.35 | P/E | -3.25 | Forward P/E | -4.41 |
| Beta | 0.35 | Short Ratio | 7.94 | Inst. Own | 96.84% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 10.14 | 200-d Avg | 9.64 | 1yr Est | 31.17 |
KURA News
– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus ca
Kura Oncology (NASDAQ:KURA) released first-quarter financial results and hosted an earnings call on
Citizens analyst Reni J. Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform
Kura Oncology, Inc. (NASDAQ:KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today
– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response r
– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients
– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated an
Dow futures down 100 points. QuickLogic (QUIK) falls after reporting worse-than-expected Q1 results.
Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.83) per share which beat the analyst co
Kura Oncology, Inc. (NASDAQ:KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today
Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") and Kura Oncology, Inc. (NASDAQ:KURA, "
Kura Oncology says kidney cancer trial data shows 44% response rate and strong disease control; anal
Lake Street analyst Daniel Brims initiates coverage on Kura Oncology (NASDAQ:KURA) with a Buy rat
Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for t
Mizuho analyst Mara Goldstein maintains Kura Oncology (NASDAQ:KURA) with a Outperform and lowers
UBS analyst David Dai maintains Kura Oncology (NASDAQ:KURA) with a Buy and lowers the price targe
Wedbush analyst Robert Driscoll maintains Kura Oncology (NASDAQ:KURA) with a Outperform and lower
Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.92) per share which missed the analyst
On Tuesday, 647 companies set new 52-week lows.
On Tuesday, 386 stocks made new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding Biomarin Pharmaceutica
Companies Reporting Before The Bell • Fresh Del Monte Produce (NYSE:FDP) is likely to report qua
Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly e
Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Wednesday
Stocks That Hit 52-Week Lows On Thursday